BLZF1

Across TCGA pan-cancer cohorts, BLZF1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BLZF1 data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BLZF1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BLZF1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, LGG, and STAD are the cancer types where BLZF1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.164	0.604	.005	29	view →
LGG	OS	Median	All	0.250	0.830	.001	12	view →
STAD	OS	Median	III,IV	0.169	0.641	.001	12	view →
LUSC	OS	Median	III,IV	0.011	0.684	<.001	12	view →
UCEC	DFS	Median	All	1.000	0.829	.016	12	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BLZF1–HNSC (DFS)

Open the HNSC breakdown →